Physician profile
William Terry
NPI 1639159155
$5,552.82
in general payments reported to CMS, 2019-2025
40 companies · $618 in 2025
The $618 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $480 · 2021: $702 · 2022: $1,203 · 2023: $1,233 · 2024: $566 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,408 · Education: $8.90.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,408.09 |
| Education | $8.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,062.17 | 2019-2024 | Lo Loestrin Fe, Orilissa, Liletta |
| Novo Nordisk INC | $971.45 | 2019-2025 | Wegovy, Saxenda |
| Daiichi Sankyo INC. | $414.52 | 2019-2023 | Injectafer |
| Pfizer INC. | $272.95 | 2019-2023 | |
| Lilly USA, LLC | $266.37 | 2024-2025 | Zepbound |
| Amgen INC. | $261.11 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $257.57 | 2023-2025 | Myfembree, Gemtesa |
| Coopersurgical, INC. | $204.93 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Astellas Pharma US INC | $157.17 | 2021-2025 | Veozah |
| Therapeuticsmd, INC. | $150.28 | 2019-2022 | |
| Avion Pharmaceuticals | $111.41 | 2021-2022 | |
| Myriad Women'S Health, INC. | $110.54 | 2023 | Myrisk |
| Evofem Biosciences, INC. | $107.52 | 2020-2023 | Phexxi |
| Axonics, INC. | $105.54 | 2021 | |
| Organon LLC | $102.20 | 2021-2025 | Nexplanon |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Terry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.